The primary therapeutic role of Parlazin (Cetirizine) is applied for symptomatic support across key domains affected by allergic responses, and may contribute to easing distress and supporting a sense of stability.

This medication is commonly used to help ease symptoms that create noticeable physiological strain during allergic episodes. This includes conditions such as seasonal and perennial allergic rhinitis and chronic idiopathic urticaria.

Symptom Management and Relief

Parlazin is considered relevant across domains where additional symptomatic support may be needed. It is relevant for managing acute or disruptive symptom patterns such as sneezing, runny nose, and ocular pruritus (itchy, watery eyes), as well as systemic itching and the manifestations of hives (urticaria). This support may contribute to easing the overall symptom burden.

“This medication is commonly used to help patients cope more steadily with symptom fluctuations, providing support during episodes of heightened discomfort.”

Quick Fact: Relief for Itching and Rhinitis

Domain	Conditions Relevant For	Primary Benefit
Allergology	Allergic Rhinitis, Chronic Urticaria	Relevant for Easing Distress
Symptom Focus	Itching, Runny Nose, Hives	May assist with Functional Stability

Regulatory References

1. NIH MedlinePlus Drug Information

The official regulatory eligibility profile for Парлазин (Cetirizine Dihydrochloride) is defined by patient-specific contraindications and conditional use requirements.

Populations for whom use is Contraindicated

Category	Official Regulatory Restriction
Hypersensitivity	Patients with known allergy to Cetirizine, any of the formulation’s excipients, or to hydroxyzine or any piperazine derivatives
Organ Function	Patients with severe renal impairment (Creatinine Clearance < 10 mL/min or End-Stage Renal Disease)

Age-Related and Conditional Eligibility

The medicine is generally established for use in adults and adolescents (12 years and older). Pediatric eligibility depends on the formulation:

• Children under 6 years: The film-coated tablet formulation is not recommended as it does not allow for necessary dose adjustment. Approval for the oral solution starts as low as 6 months of age for certain indications.
• Moderate to Severe Renal Impairment: Patients with decreased kidney function (e.g., CrCL < 50 mL/min) are eligible, but the regulatory labeling requires that the dose be formally reduced or adjusted.
• Pregnancy and Lactation: Use during pregnancy is classified as requiring caution, and is generally recommended only if clearly needed due to limited human data. Caution is also advised during breastfeeding, as Cetirizine is excreted into human milk.

Eligibility-Related Restrictions

Official documents specifically advise that caution should be exercised in patients with predisposition factors for urinary retention and in patients with epilepsy or those at risk of convulsions.

The official interaction profile for Parlazin (Cetirizine) is primarily characterized by pharmacodynamic augmentation and specific pharmacokinetic considerations documented in regulatory labeling.

Regulatory documentation advises that concurrent use with alcohol or other Central Nervous System (CNS) depressants, such as sedatives and tranquilizers, must be avoided. This restriction is due to the potential for an additive effect that may lead to additional reduction in alertness and impairment of CNS performance.

A specific pharmacokinetic interaction is noted with Theophylline (400 mg once daily), where co-administration results in a small decrease (approximately 16%) in the clearance of cetirizine. Conversely, studies with Azithromycin, Erythromycin, Ketoconazole, and Pseudoephedrine have shown no clinically significant drug interactions.

Interaction Entity	Official Regulatory Effect
Alcohol / CNS Depressants	Avoid concurrent use; risk of additive CNS impairment.
Theophylline (400 mg daily)	Results in reduced clearance of Cetirizine.
Food	Delays time to peak plasma concentration (Tmax).

While food delays the time to reach peak plasma concentration (Tmax), it does not alter the overall extent of the drug's absorption. Furthermore, regulatory documents specify that dose consideration may be necessary for patients with liver or kidney disease, as well as for geriatric patients who may experience prolonged elimination and lower clearance, factors relevant to managing interaction-related effects.

Targeted Blockade of H1 Histamine Receptors

This compound's primary action is to function as a selective antagonist, specifically blocking the H1 histamine receptors found outside the central nervous system. This direct action halts the downstream signaling cascade typically initiated by the body's release of histamine, which modifies the subsequent cellular activity.

Physiological Modulation of Permeability and Secretion

By preventing H1 receptor activation, the mechanism modifies the physiological response of key tissues, resulting in a reduction of capillary permeability and subsequent extravasation. This core mechanism influences the body's vascular response and modulates exocrine secretion resulting from heightened signaling activity.

Influence on Inflammatory Cell Dynamics

Beyond receptor antagonism, the mechanism includes inducing stabilization of certain inflammatory cells, such as mast cells, and interfering with the chemotaxis (migration) of other immune cells like eosinophils. This supplementary action contributes to reducing the overall local concentration of inflammatory mediators, modulating the subsequent physiological reaction.

Instruction Map: How to Use Парлазин — Official Administration Guidelines

Administration Scope

The administration of Cetirizine Dihydrochloride is strictly oral, available in film-coated tablets (5 mg and 10 mg) and as an oral solution or drops. For adults and adolescents 12 years of age and older, the standard labeled regimen is 10 mg once daily, although a starting dose of 5 mg may be administered for less severe symptoms. The total intake must not exceed 10 mg in a 24-hour period. The medication may be taken with or without food, as official data indicates that food does not significantly alter the overall extent of absorption.

Population-Specific Dosing Adjustments

Official guidelines mandate that the dosing frequency or amount must be modified for certain patient populations, establishing a constraint on routine use. For patients with moderate renal impairment (creatinine clearance 30–49 mL/min), the dose is typically reduced to 5 mg once daily. In cases of severe renal impairment (<30 mL/min), the dose should be reduced to 5 mg once every two days. No dose reduction is typically necessary for patients with isolated hepatic impairment, provided kidney function is normal.

Age Group	Standard Oral Regimen	Key Administration Rule
Adults (12 yrs)	10 mg once daily	Maximum 10 mg per 24 hours.
Children 6–12 yrs	5 mg twice daily or 10 mg once daily	Tablets are not suitable for children under 6 years due to dose adjustment difficulty.

Resulting Procedural Structure

The official protocol is procedural and relies on consistent daily intake. If a dose is missed, patients should continue with the original schedule, taking the next dose at the regular time without doubling the amount to compensate for the skipped dose. This procedure ensures the fixed, once-daily pattern is maintained.

Research Evidence / Overview of Studies for Парлазин

---

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring the role of this medicine for seasonal and perennial allergic rhinitis is primarily based on Randomized Controlled Trials (RCTs) and meta-analyses that consolidate findings from many individual trials. These studies were designed to examine symptom changes over defined time intervals, often comparing the medicine against an inactive placebo or against certain other anti-allergy medications. Outcomes measured included both clinician assessments and patient-reported outcomes describing perceived discomfort related to nasal symptoms and ocular symptoms.

Studies report how symptoms evolved in the observed adult populations. The research highlights changes measured during short-term study periods, describing measured changes in symptom intensity compared to placebo in trials assessing short-term or episodic symptom patterns. Active-comparator trials explored measured changes against those observed with certain other anti-allergy treatments.

---

Evidence for Use in Chronic Urticaria

For chronic urticaria, a condition characterized by fluctuating manifestations of hives and itching, the research primarily consists of short-term, placebo-controlled RCTs and systematic reviews. Studies were used in research contexts involving fluctuating or unstable symptoms. Outcomes related to physical discomfort were monitored, specifically the extent of wheal (hive) appearance and the severity of pruritus (itching).

Research describes patterns observed in the studies related to symptom intensity over defined short time intervals, with findings indicating measured changes in wheal and itching severity compared to placebo in the observed populations. The overall evidence quality for symptom measurement in chronic urticaria is generally described as High in scientific assessments. However, the duration of most published RCTs is short, which limits the assessment of consistent changes in symptom measurements for this condition over extended periods.

---

Evidence in Special Populations and Research Gaps

Research has explored the use of this medicine in specific demographics, including children and older adults. In children, studies explored short-term symptom changes in conditions associated with acute or disruptive episodes. Findings help contextualize how patients reported their experience and contribute to understanding symptom patterns in various age groups.

Conversely, data for certain groups remain insufficient. For instance, efficacy evaluations did not consistently include an adequate number of patients aged 65 and older to establish whether data show patterns related to measured symptom changes compared to younger adults. Long-term outcomes are not fully established across all populations, and research is ongoing to fully contextualize the evidence landscape.

Common questions about Парлазин (FAQ)

Q: Is it necessary to take Парлазин every day, or just when needed?

A: According to official guidance, this medicine can be used in two ways. It may be taken as a one-off dose when symptoms appear, or it can be taken consistently every day for a longer time to help prevent symptoms. The approach used may depend on the condition, and is typically determined by a healthcare provider.

Q: Can older adults use Парлазин safely?

A: Official product information notes that individuals 65 years and older may have increased sensitivity to adverse effects. Because of this, prescribing information advises caution, and a lower dosage is often considered for this population.

Q: What is the difference between Парлазин and other over-the-counter allergy medications?

A: The medicine is classified as a second-generation H1-antihistamine. This means it is generally described in official sources as a 'non-drowsy' type. This chemical structure makes it less likely to cause sleepiness compared to older antihistamines.

Q: Why is Парлазин sometimes preferred over older generation allergy drugs?

A: Its classification as a modern, non-drowsy antihistamine contributes to its common use. Regulatory information suggests it is less likely to cause common side effects seen with older medications, such as significant sleepiness or anticholinergic effects like dry mouth.

Q: Are there specific foods or drinks to avoid while taking Парлазин?

A: Official interaction guidelines state that concurrent use with alcohol should be avoided due to the potential for additive depressant effects on the central nervous system. Other than alcohol, regulatory documents report no known specific food or non-alcoholic drink interactions, and the medication may be taken with or without a meal.

Q: Does using Парлазин long-term pose any particular health risks?

A: For individuals using the medicine continuously for an extended period, official safety warnings describe a potential for intense itching or hives to occur upon sudden discontinuation. Prescribing information guides its use for symptom relief.

Q: Is there any research that looks at how Парлазин affects driving ability?

A: While the medicine is a non-drowsy type, official regulatory labeling includes specific warnings related to mental alertness and CNS effects. These warnings recommend caution when operating heavy machinery or driving, as effects like drowsiness, dizziness, or decreased attention may still occur in some individuals.

Q: What are the typical indications for which doctors prescribe Парлазин?

A: According to official regulatory documents, the medicine is approved to relieve symptoms of seasonal allergic rhinitis, which is commonly known as hay fever. It is also approved for perennial (year-round) allergic rhinitis and for managing chronic idiopathic urticaria, which is a form of persistent hives.

Q: Is Парлазин used for non-allergic conditions, or strictly for allergies?

A: The approved uses for the single-ingredient formulation are focused primarily on conditions caused by allergic reactions. These indications include allergic rhinitis (hay fever) and chronic urticaria (hives).

Q: How quickly does Парлазин start to work after taking it?

A: Studies indicate that the effects of the medicine generally begin fairly quickly after administration. Relief from symptoms typically starts within a timeframe of 30 to 60 minutes after taking the dose.

Q: How long do the effects of Парлазин usually last?

A: This medicine is designed for once-daily use. The standard dosing regimen is intended to provide sustained relief, and the effects are typically maintained for a full 24-hour period.

Q: Is there a risk of developing tolerance to Парлазин over time?

A: The development of tolerance is not listed as a common effect in the official prescribing information. Furthermore, studies on how the body processes the medicine over time suggest there is no accumulation of the drug with consistent, long-term administration.

Q: Can I drink coffee while taking Парлазин?

A: Regulatory interaction checkers do not report a specific drug interaction between the medicine and caffeine. However, because the medicine can cause drowsiness in some individuals, it is prudent to consult with a healthcare provider regarding combining it with stimulants like coffee.

Q: Are there any known interactions between Парлазин and herbal supplements?

A: Regulatory documents do not contain formal reports of specific interactions between this medicine and herbal supplements. However, safety data is often limited for all such combinations. For comprehensive guidance, official sources suggest reviewing potential use of herbal products with a healthcare provider.

Q: Can Парлазин be used to treat symptoms of the common cold?

A: The single-ingredient medicine is officially indicated for relieving symptoms caused by allergies, such as allergic rhinitis. It is not the primary approved purpose of this drug to treat symptoms associated with the common cold.

Q: Can taking too much Парлазин cause serious problems?

A: Regulatory guidance describes that any dose exceeding the recommended amount may result in serious effects. These symptoms include drowsiness, agitation, headache, and a rapid heart rate (tachycardia), and are considered a serious event.

Q: Is there a generic version of Парлазин available?

A: Yes, the active component of this medicine, Cetirizine Dihydrochloride, is recognized globally. It is widely available for purchase under various generic and store-brand labels.

Q: Does Парлазин help with indoor allergies like dust mites or pet dander?

A: Yes, the official indications for this medicine include perennial allergic rhinitis. This is the medical term for year-round symptoms, which are often caused by common indoor allergens such as dust mites, mold spores, and pet dander.

Q: Is it okay to take Парлазин if I have glaucoma?

A: Regulatory prescribing information does not list glaucoma as a specific contraindication or official caution for use. Unlike some older allergy medicines, this drug is not known to exhibit the strong anticholinergic effects that may cause concern for individuals with glaucoma.

Q: Can Парлазин interfere with the results of an allergy skin test?

A: Regulatory guidance for allergy testing confirms that this medicine can interfere with skin test results. Due to this potential interference, healthcare providers usually require the oral antihistamine to be stopped for a specified period (often 5 days) before the test is performed.

Q: How is Парлазин processed by the body?

A: Official pharmacokinetic data shows that the medicine is well absorbed by the body. Unlike many other drugs, it is primarily excreted unchanged through the kidneys, with very little being metabolized by the liver's main enzyme systems.

Q: Are there any specific warnings about taking Парлазин before surgery?

A: Regulatory guidance on pre-operative medication suggests that this medicine can generally be continued without interruption before major surgical procedures. It is not commonly associated with risks related to surgical bleeding or dangerous interactions with anesthesia.

Q: Does Парлазин lose its effect if I stop and restart it later?

A: Official product information does not state that the medicine will lose effectiveness if it is stopped and then restarted later. In fact, regulatory documents note that if withdrawal-related symptoms occur upon stopping the medicine, those symptoms often improve when the medicine is restarted.

How to Store and Dispose of Парлазин (Parlazin)

The storage and disposal of Парлазин (Cetirizine Dihydrochloride) must align strictly with regulatory labeling to maintain stability and safety.

Storage Conditions

Requirement	Condition
Temperature	Store at a temperature no higher than 25°C (store below 25, C).
Protection	Must be stored protected from light and kept in a dry place.
Freezing	Oral drop formulations have an explicit instruction: Do not freeze!

The medicine must be stored out of the sight and reach of children.

Stability and Disposal

The oral drops have a limited in-use stability; they must be used within 4 weeks (28 days) after the bottle is first opened. The product must be stored in its original packaging and not used after the expiration date.

For disposal, the medicine must not be thrown into household trash or wastewater. Unused or expired medication must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.